» Articles » PMID: 22016029

Silymarin Inhibits Cervical Cancer Cell Through an Increase of Phosphatase and Tensin Homolog

Overview
Journal Phytother Res
Publisher Wiley
Date 2011 Oct 22
PMID 22016029
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Silymarin is an active constituent contained in the seeds of the milk thistle plant and is widely used as a hepatic protection agent due to its antioxidant-like activity. In the present study we evaluated the potential action of silymarin against cervical cancer and investigated its mechanism of action. Treatment of cervical cancer cells (C-33A) with silymarin resulted in a significant decrease in cell viability. Silymarin induced apoptosis through the modulation of Bcl-2 family proteins and activation of caspase 3. Silymarin also inhibited the phosphorylation of Akt with an increase in expression of phosphatase and tensin homolog (PTEN). We also observed that silymarin suppressed C-33A cell invasion and wound-healing migration in a concentration-dependent manner. Western-blot analysis showed that silymarin significantly inhibited the expression of matrix metalloproteinase-9 (MMP-9) in C-33A cells. Furthermore, we applied siRNA to lower the PTEN gene, which diminished the anticancer actions of silymarin. Taken together, these results show that silymarin has the potential to suppress the survival, migration and invasion of C-33A cancer cells; thus, it could be developed as a promising agent for the treatment of cervical cancer in the future.

Citing Articles

Mechanistic Insights into Silymarin-Induced Apoptosis and Growth Inhibition in SPC212 Human Mesothelioma Cells.

Tomsuk O, Kacar S Cell Biochem Biophys. 2025; .

PMID: 39747779 DOI: 10.1007/s12013-024-01650-w.


A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment.

Ray P, Islam M, Islam M, Han A, Geng P, Aziz M Front Pharmacol. 2024; 15:1349745.

PMID: 38487172 PMC: 10937417. DOI: 10.3389/fphar.2024.1349745.


The Radiosensitizing Potentials of Silymarin/Silibinin in Cancer: A Systematic Review.

Gupta J, Turki Jalil A, Riyad Muedii Z, Aminov Z, Alsaikhan F, Ramirez-Coronel A Curr Med Chem. 2023; 31(42):6992-7014.

PMID: 37921180 DOI: 10.2174/0109298673248404231006052436.


A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity.

Singh M, Kadhim M, Turki Jalil A, Oudah S, Aminov Z, Alsaikhan F Cancer Cell Int. 2023; 23(1):88.

PMID: 37165384 PMC: 10173635. DOI: 10.1186/s12935-023-02936-4.


Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Koltai T, Fliegel L J Evid Based Integr Med. 2022; 27:2515690X211068826.

PMID: 35018864 PMC: 8814827. DOI: 10.1177/2515690X211068826.